SCHEMBL16619009

SCHEMBL16619009

NCc1csc(-c2ccccc2Cl)n1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.73
L3MBTL1 Q9Y468 2/20 0.73
TDP1 Q9NUW8 1/20 0.73
CYP19A1 P11511 1/20 0.46
DPP4 P27487 2/20 0.46
KDM4E B2RXH2 4/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
NPC1 O15118 3/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
HTR2C P28335 1/20 0.44
HTT P42858 1/20 0.43
ADORA1 P30542 1/20 0.41
ATP4A P20648 2/20 0.41
ATP4B P51164 2/20 0.41
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619626 0.87 L3MBTL1 (0.69) ALDH1A1L3MBTL1TDP1CYP19A1DPP4
SCHEMBL2431805 0.84 ALDH1A1 (1.00) ALDH1A1L3MBTL1TDP1CYP19A1KDM4E
SCHEMBL18015824 0.83 ALDH1A1 (0.73) ALDH1A1L3MBTL1TDP1CYP19A1KDM4E
SCHEMBL5895082 0.83 ALDH1A1 (0.73) ALDH1A1L3MBTL1TDP1CYP19A1KDM4E
SCHEMBL18015816 0.80 L3MBTL1 (0.69) ALDH1A1L3MBTL1TDP1CYP19A1KDM4E
SCHEMBL5930632 0.80 ALDH1A1 (0.69) ALDH1A1L3MBTL1TDP1CYP19A1KDM4E
SCHEMBL18014690 0.79 ALDH1A1 (0.67) ALDH1A1L3MBTL1TDP1CYP19A1KDM4E
SCHEMBL21115997 0.79 ALDH1A1 (0.67) ALDH1A1L3MBTL1TDP1CYP19A1KDM4E
SCHEMBL590109 0.77 KDM4E (0.62) L3MBTL1KDM4EHPGDNPC1MAPT
SCHEMBL18014691 0.76 L3MBTL1 (0.63) ALDH1A1L3MBTL1TDP1CYP19A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052495-B1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS PFIZER (US) 2019-06-26 EP disclosed
US-20160229847-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS PFIZER (US) 2016-08-11 US disclosed
EP-3052495-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS Pfizer Inc. (US) 2016-08-10 EP disclosed
WO-2015049616-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS PFIZER INC. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229847-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS BACE1, BACE2, PSEN2 ALDH1A1 1923/4885L3MBTL1 4677/4885TDP1 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.